Actively Recruiting
Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
Led by University of Malaya · Updated on 2026-01-27
150
Participants Needed
4
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
CONDITIONS
Official Title
Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older
- Histologically confirmed stage IV non-small cell lung cancer (NSCLC)
- Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
- Treated with at least one cycle of first-line chemotherapy
You will not qualify if you...
- Received targeted therapy or immunotherapy as first-line monotherapy
- Incomplete survival data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Queen Mary Hospital, The University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
2
Hospital Tengku Ampuan Afzan
Kuantan, Pahang, Malaysia
Actively Recruiting
3
Hospital Wanita dan Kanak-Kanak Sabah
Kota Kinabalu, Sabah, Malaysia
Actively Recruiting
4
Universiti Malaya Medical Centre
Kuala Lumpur, Malaysia
Actively Recruiting
Research Team
M
Mau Ern Poh, MBBS
CONTACT
D
Danouska Bala Krishnan
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here